Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection– 7 days or less versus longer treatment: Systematic review and meta-analysis of randomized controlled trials.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute pyelonephritis is a frequent cause of morbidity, with a wide variation in duration of therapy. We performed a systematic review of all randomized controlled trials (RCTs) comparing ≤7 days treatment with a longer course. METHODS: Electronic databases were searched to identify RCTs that assessed adults treated for pyelonephritis, comparing a 7 day or shorter versus longer therapy. Primary outcome was clinical failure at the end of the long treatment arm (EOT). Secondary outcomes included clinical failure at the end of follow-up (EOF), microbiological failure, all-cause mortality, the development of resistance and adverse events. RESULTS: Clinical failure at EOT did not significantly differ between the two treatment arms [relative risk (RR) 0.63, 95% CI 0.33-1.18, I(2) = 41%]. Results did not differ when including studies comparing only fluoroquinolones, reducing the heterogeneity (RR 0.76, 95% CI 0.49-1.17, I(2) = 0%). We found no difference between the short and long treatment arms regarding clinical failure at EOF, even in a small subgroup of bacteraemic patients. No difference was found between the arms regarding microbiological failure at EOF, except in a subgroup of studies with a high percentage of patients with urogenital abnormalities, where microbiological failure at EOF was significantly higher in the short treatment arm (RR 1.78, 95% CI 1.02-3.10, I(2) = 21%). Adverse events were similar between the arms. CONCLUSIONS: Seven days of treatment for acute pyelonephritis is equivalent to longer treatment in terms of clinical failure and microbiological failure, including in bacteraemic patients. In patients with urogenital abnormalities, the evidence, although weak, suggests that longer treatment is required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In many of the trials, the shorter course was just as effective as the longer course but associated with fewer adverse consequences.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [290]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Management of Urinary Tract Infections in Adults
Desforges, J. F., Stamm, W. E., & Hooton, T. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291808 · Cited by 899
Has the era of untreatable infections arrived?
Livermore, D. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp255 · Cited by 620
Population-Based Epidemiologic Analysis of Acute Pyelonephritis
Czaja, C. A., Scholes, D., Hooton, T. M., & Stamm, W. E. (2007) · Clinical Infectious Diseases · doi:10.1086/519268 · Cited by 337
Rice, L. B. (2008) · Clinical Infectious Diseases · doi:10.1086/526535 · Cited by 200
Sandberg, T., Skoog, G., Hermansson, A. B., Kahlmeter, G., Kuylenstierna, N., Lannergård, A., Otto, G., Settergren, B., & Ekman, G. S. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60608-4 · Cited by 189
Peterson, J., Kaul, S., Khashab, M., Fisher, A. C., & Kahn, J. B. (2008) · Urology · doi:10.1016/j.urology.2007.09.002 · Cited by 187
Huang, E. S., & Stafford, R. S. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.1.41 · Cited by 148
Lessons From and Cautions About Noninferiority and Equivalence Randomized Trials
Gøtzsche, P. C. (2006) · JAMA · doi:10.1001/jama.295.10.1172 · Cited by 106
Current Antibiotic Therapy for Isolated Urinary Tract Infections in Women
Kallen, A. J., Welch, H. G., & Sirovich, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.6.635 · Cited by 105
Klausner, H. A., Brown, P., Peterson, J., Kaul, S., Khashab, M., Fisher, A. C., & Kahn, J. B. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x233340 · Cited by 85
Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin
BOWIE, W. R., Willetts, V., & Jewesson, P. J. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1778 · Cited by 79
JERNELIUS, H., ZBORNIK, J., & BAUER, C. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15899.x · Cited by 62
O’Connor, P. J., Solberg, L. I., Christianson, J. B., Amundson, G. H., & Mosser, G. (1996) · The Joint Commission Journal on Quality Improvement · doi:10.1016/s1070-3241(16)30274-7 · Cited by 59
Kyriakidou, K. G., Rafailidis, P. I., Matthaiou, D. K., Athanasiou, S., & Falagas, M. E. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.10.007 · Cited by 49
Variability of treatment duration for bacteraemia in the critically ill: A multinational survey.
Corona, A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg447 · Cited by 43
Corona, A., Wilson, A. P. R., Grassi, M., & Singer, M. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh416 · Cited by 35
de Gier, R. P. E., Karperien, A., Bouter, K. P., Zwinkels, M. G. J., Verhoef, J., Knol, W., Boon, T. A., & Hoepelman, I. M. (1995) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(95)00011-v · Cited by 33
Ode, B., Bröms, M., Walder, M., & Cronberg, S. (1980) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1980.tb09725.x · Cited by 24
Kahan, N. R., CHINITZ, D. P., & Kahan, E. (2004) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2003.00537.x · Cited by 19
(2016) · Dental Abstracts · doi:10.1016/j.denabs.2015.07.010 · Cited by 4
Short-course treatment of bacteremia with ceftriaxone monotherapy.
Wang, L. S., Cheng, D. L., Hinthorn, D. R., et al. (1990) · PubMed · Cited by 2
Corona, A., Cislaghi, F., Raimondi, F., & Singer, M. (2008) · PubMed · Cited by 2
Talan, D. A., Stamm, W. E., Hooton, T. M., Moran, G. J., Burke, T., Iravani, A., Reuning-Scherer, J., & Church, D. A. (2000) · JAMA · doi:10.1001/jama.283.12.1583
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
“Similarly, studies have shown that a treatment duration of <7 days is as effective as longer durations in the management of acute pyelonephritis with or without bacteremia [201], uncomplicated cellulitis [203], and spontaneous bacterial peritonitis [204].”
BackgroundSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Yahav, D., Franceschini, E., Koppel, F., Turjeman, A., Babich, T., Bitterman, R., Neuberger, A., Ghanem-Zoubi, N., Santoro, A., Eliakim-Raz, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1054 · Cited by 433
“Several randomized controlled trials (RCTs) demonstrated no significant difference between short and long antibiotic courses in the treatment of mainly gram-negative infections such as pyelonephritis [3] and complicated intra-abdominal infections [4, 5].”
BackgroundSelf-citation
Metadata
- Authors
- Eliakim-Raz, N., Yahav, D., Paul, M., & Leibovici, L.
- Affiliations
- Tel Aviv University (IL)
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-21
- Volume
- 68
- Issue
- 10
- Pages
- 2183-2191
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2101077702
- Semantic Scholar
- 589a6d5a4f5739aafc0c3bc04deca7f5a6da1b9f
- Cited by
- 153
- References
- 26
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 10 · 2023: 16 · 2022: 16 · 2021: 12 · 2020: 25 · 2019: 7 · 2018: 16 · 2017: 17 · 2016: 5 · 2015: 7 · 2014: 1 · 2013: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pediatric Urology and Nephrology Studies
- Keywords
- acute pyelonephritis, antibiotic duration, short-course antibiotic therapy, fluoroquinolones, bacteremia, genitourinary anomalies, microbiological failure, antimicrobial resistance, adverse events, mortality
- MeSH terms
- Anti-Bacterial Agents, Bacterial Infections, Humans, Pyelonephritis, Time Factors, Urinary Tract Infections, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.